Why Vendor Selection Is the Hidden Bottleneck in Clinical Trials

A market doubling in size — but not in efficiency

The contract research organisation (CRO) industry is on track to nearly double from $92 billion in 2025 to $200 billion by 2034. That growth is driven by increasing trial complexity, expanding therapeutic areas, and the sheer volume of drugs moving through the pipeline — over 83,000 trials are actively recruiting right now.

But scale without selection discipline creates drag. The top 10 CROs — IQVIA, ICON, Fortrea, Thermo Fisher/PPD, Syneos Health, WuXi, Parexel, Pharmaron, and others — control roughly 65% of the market. That concentration means sponsors who default to the biggest name are often paying a premium without verifying whether that vendor is actually the best fit for their therapeutic area, geography, or trial phase.

The real cost isn't the CRO invoice — it's the delay

The average Phase 3 trial costs $19 million and runs for roughly three years. When 85% of trials fail to enrol on time, the downstream cost isn't just a delayed invoice — it's extended site contracts, stalled regulatory timelines, and competitive exposure. Every month of delay erodes patent life and market position.

Site selection is consistently identified as the bottleneck. But site selection is a vendor decision. The CRO or site network you choose determines patient access, geographic reach, and recruitment velocity. Getting that choice wrong is the single most expensive invisible cost in clinical development.

Oncology dominates — but the principle applies everywhere

Oncology accounts for roughly 35% of all clinical trial activity. It's where the most money, the most competition, and the most vendor specialisation converge. But the same selection dynamics play out across infectious disease, central nervous system disorders, rare diseases, and medical devices. In every therapeutic area, the vendors with the deepest site relationships and the most relevant enrolment track record are rarely the ones with the biggest marketing budgets.

Why vendor evidence matters more than vendor marketing

Most vendor selection today relies on RFP responses, personal relationships, and brand recognition. These are useful signals, but they're incomplete. What's missing is structured, comparable evidence about how vendors actually perform — not what they say they'll do, but what they've delivered.

That's the gap Clinical Vendor Compare exists to fill. Not by replacing sponsor judgement, but by giving decision-makers the evidence layer they need to make faster, more confident vendor choices — before the enrolment clock starts ticking.